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Purpose: To compare the dosimetric differences between jaw tracking technique (JTT) and static jaw technique
(SJT) in dynamic intensity-modulated radiotherapy (d-IMRT) and assess the potential advantages of jaw tracking
technique.
Methods: Two techniques, jaw tracking and static jaw, were used respectively to develop the d-IMRT plans for 28
cancer patients with various lesion sites: head and neck, lungs, esophageal, abdominal, prostate, rectal and cervical.
The dose volume histograms (DVH) and selected dosimetric indexes for the whole body and for organs at risk
(OARs) were compared. A two dimensional ionization chamber Array Seven29 (PTW, Freiburg, Germany) and
OCTAVIUS Octagonal phantom (PTW, Freiburg, Germany) were used to verify all the plans.
Results: For all patients, the treatment plans using both techniques met the clinical requirements. The V5, V10, V20,
V30, V40 (volumes receiving 5, 10, 20, 30 and 40 Gy at least, respectively), mean dose (Dmean) for the whole body
and V5, V10, V20, Dmean for lungs in the JTT d-IMRT plans were significantly less than the corresponding values of the
SJT d-IMRT plans (p < 0.001). The JTT d-IMRT plans deposited lower maximum dose (Dmax) to the lens, eyes,
brainstem, spinal cord, and right optic nerve, the doses reductions for these OARs ranged from 2.2% to 28.6%.
The JTT d-IMRT plans deposited significantly lower Dmean to various OARs (all p values < 0.05), the mean doses
reductions for these OARs ranged from 1.1% to 31.0%, and the value reductions depend on the volume and the
location of the OARs. The γ evaluation method showed an excellent agreement between calculation and
measurement for all techniques with criteria of 3%/3 mm.
Conclusions: Both jaw tracking and static jaw d-IMRT plans can achieve comparable target dose coverage. JTT
displays superior OARs sparing than SJT plans. These results are of clinical importance, especially for the patients
with large and complex targets but close to some highly radio-sensitive organs to spare, and for patients with local
recurrent or secondary primary malignant lesion within a previously irradiated area.
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Nowadays, dynamic intensity-modulated radiotherapy
(d-IMRT) is widely used in the treatment of cancer
patients. Compared with three dimensional conformal
radiotherapy, d-IMRT allows to increase the dose con-
formity of the target while decreasing normal tissue
doses [1].* Correspondence: suxu@nirp.cn
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unless otherwise stated.In dynamic IMRT plans, the multi-leaf collimators
(MLCs) translate continuously at variable speeds during
the irradiation while the upper and lower jaws stay
static. According to the study by LoSasso et al. [2], the
MLC transmission increases with increasing jaw field
size and beam energy. Cadman et al. [3] found that the
transmission through the jaw and the MLC together is
smaller than 0.1%. Jaw tracking technique provided by
linear accelerators keeps jaws during dose delivery as
close as possible to the MLC aperture, and further mini-
mizes leakage and transmission through the MLC leaves.his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tracking in step-and-shoot IMRT, but failed to indicate
which patients would benefit most from jaw tracking.
The dosimetric benefits of jaw tracking for prostate
and head and neck (H&N) patients using d-IMRT and
volumetric-modulated arc therapy (VMAT) were also
evaluated by others [5,6]. It showed that, the organs far
from the target showed larger sparing in jaw-tracking
static arc than the organs adjacent to the target. True-
Beam (Varian Medical Systems, Palo Alto, CA) is a new
generation of linear accelerator providing jaw tracking
technique (JTT), which traces the MLC aperture with
jaws to minimize the leakage and transmission of the
MLC leaves, hence further reduces the OAR doses adja-
cent to the target, and potentially improves the dose fall-
off towards the surrounding critical structures.
The main purpose of this study is to assess the poten-
tial advantages of the JTT provided by TrueBeam ac-
celerators in reducing the doses to the organs at risk
(OARs) while preserving adequate target dose coverage,
and to evaluate which patients and which OARs would
benefit most from JTT plans.
Materials and methods
Ethical consideration and consent
The use of the radiotherapy database for retrospective
research has been approved by the committee of the
Ethical Review Board of the Chinese Center for Disease
Control and Prevention (No. LLSC2014-005). This re-
search was waivered informed consent.
Patient characteristics
Twenty eight cancer patients (median age 58 years, range
31–77 years) treated with radiotherapy in our department
were retrospectively included in this study. The lesion
distributions of the selected cases included head and
neck, lungs, esophageal, abdominal, prostate, rectal and
cervical, as shown in Table 1. One local recurrent naso-
pharyngeal carcinoma (NPC) patient was included in
the H&N group.Table 1 Lesion distributions and treatment characteristics of
Lesion sites n Total dose (Gy)
GTV
Mean dose (range)







Abbreviations: SD standard deviation.Contouring of targets and OARs
All patients were immobilized with custom-made ther-
moplastic mask and underwent computed tomography
(CT) scan with slice thickness of 3 mm (for head and
neck patients) or 5 mm (for thoracic, abdominal and pel-
vic patients ) using the Siemens Somatom Sensation Open
40 slice CT scanner (Siemens, Forchheim, Germany). The
targets and OARs were contoured slice by slice on the
treatment planning CT images. Relevant organs were de-
lineated for different anatomic regions. The body was
segmented automatically by the Eclipse (Versions 11.0)
Treatment Planning System (TPS) (Varian Medical Sys-
tems, Palo Alto, CA). Isotropic margins of 3 mm (for head
and neck patients) or 5 mm (for thoracic, abdomen and
pelvic patients) were created around the clinical target vol-
ume (CTV) and gross tumor volume (GTV) to generate
the planning target volume (PTV) and planning gross
tumor volume (PGTV), respectively.
Treatment planning
The static jaw technique (SJT) d-IMRT plans were created
using the Eclipse TPS using sliding window dynamic deliv-
ery and fixed beam angles. The selected energies were 6 MV
(for head and neck patients) and 10 MV (for thoracic, ab-
dominal and pelvic patients) respectively from a TrueBeam
linear accelerator. The collimator angles were optimized ac-
cording to the target shape. After IMRT optimization using
the dose volume optimizer algorithm (version 11.0.31), the
volumetric doses were calculated using the anisotropic ana-
lytical algorithm (version 11.0.31) with a dose calculation
grid of 2 mm. The reference volume for the treatment plan-
ning was PTV. The normal tissue dose volume constraints
used for the treatment planning are listed in Table 2. For all
patients, the dose distributions met the planning require-
ments, i.e. at least 95% of the PTV received the prescribed
dose, while the doses to the surrounding tissues were mini-
mized. To create JTT d-IMRT plans, the SJT d-IMRT plans
were duplicated and jaw tracking function was selected
when calculating the leaf motions and volumetric doses. All
the machine parameters and optimization parameters werethe selected cases
PTV (cm3)
CTV








Table 2 Dose constraints used in treatment planning
Organ Dose volume parameters Organ Dose volume parameters
Lens Dmax < 7Gy Heart Dmean < 26Gy
Eye Dmax < 50Gy V30 < 50%
Dmean < 35Gy Liver Dmean < 30Gy
Optic nerve Dmax < 54Gy 1/3 volume of liver avoid irradiation
Brain stem Dmax < 54Gy Kidney Dmean < 18Gy
Parotid V30 < 50% V12 < 55%
Dmean < 26Gy V20 < 32%
Spinal cord Dmax < 40Gy Intestine V40 < 30%
Esophagus V35 < 50% Bladder V30 < 50%
Dmean < 34Gy Femoral Head V20 < 50%
Lung V5 < 70% V30 < 15%
V10 < 50% Rectum V30 < 50%
V20 < 30% V60 < 35%
Dmean < 15Gy V70 < 20%
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reduce the dose leakage and transmission through the
MLCs, which required renormalization to achieve the same
PTV coverage as in the SJT d-IMRT plans.
Plan evaluation
The DVHs and the isodose curves of the JTT plans were
compared with that of the SJT plans. The dose changes
to the whole body were evaluated using V5, V10, V20,
V30, V40, Dmax and Dmean as listed in Table 3. The pa-
rameters of V5, V10, V20, Dmax, and Dmean were used to
evaluate the dose changes to the lungs, as shown in
Table 4. The dosimetric disparities of OARs were evalu-
ated using the maximum dose (Dmax) and mean dose
(Dmean) as listed in Table 5 and Table 6.
Plan verification
The Eclipse TPS was used to create plans for verification
by converting the SJT and JTT plans to OCTAVIUS
Octagonal phantoms (PTW, Freiburg, Germany). Then
the volumetric doses were re-calculated, and the doseTable 3 Comparison of the whole body doses between
the two techniques (X  s)
Body SJT JTT p
V5 (%) 37.2 ± 19.1 36.1 ± 18.6 <0.001
V10 (%) 29.0 ± 16.5 28.2 ± 16.0 <0.001
V20 (%) 19.9 ± 12.9 19.3 ± 12.4 <0.001
V30 (%) 12.0 ± 9.6 11.6 ± 9.2 <0.001
V40 (%) 7.6 ± 7.0 7.5 ± 6.9 <0.001
Dmax(Gy) 60.3 ± 8.5 60.5 ± 8.8 0.071
Dmean(Gy) 9.8 ± 6.0 9.6 ± 5.8 <0.001distributions in effective measurement points of the
two dimensional ionization chamber Array Seven29
(PTW, Freiburg, Germany) were exported for all plans.
By using the γ evaluation method of VeriSoft software
(version 5.1) (PTW, Freiburg, Germany), the measured
dose planes were compared with the computed dose
distribution using criteria of 3% dose difference and
3 mm distance to agreement.Statistical analysis
The data were presented as the averages of all patients
followed by the standard deviation ( X  s). The PASW
Statistics (version 18.0) software (SPSS; Chicago, IL,
USA) was applied for statistical analysis. To compare the
results of the two techniques, Wilcoxon Signed-Ranks
test was performed with p values <0.05 considered as
significant.Results
As shown in the DVH comparison (Figure 1), JTT d-
IMRT plans reduce doses to the normal tissues, espe-
cially in the low dose regions.Table 4 Comparison of lung doses between the two
techniques (X  s)
Lung SJT JTT p
V5 (%) 48.3 ± 6.7 45.7 ± 5.9 <0.001
V10 (%) 34.9 ± 6.2 33.6 ± 5.8 <0.001
V20 (%) 20.5 ± 5.5 19.9 ± 5.1 <0.001
Dmax(Gy) 59.9 ± 6.4 60.00 ± 6.5 0.155
Dmean(Gy) 11.4 ± 2.6 11.0 ± 2.5 <0.001
Table 5 Comparison of OARs Dmaxbetween the two
techniques (X  s)
OARs Dmax(Gy) SJT JTT p
Right lens 5.6 ± 2.2 4.00 ± 1.7 0.031
Left lens 5.7 ± 1.6 4.2 ± 1.3 0.031
Right eye 26.3 ± 17.3 24.5 ± 17.8 0.031
Left eye 26.6 ± 13.9 24.9 ± 14.9 0.031
Right optic nerve 44.3 ± 8.9 43.4 ± 8.7 0.031
Left optic nerve 41.8 ± 10.8 40.8 ± 12.0 0.156
Brain stem 39.1 ± 12.0 37.2 ± 12.9 0.016
Right parotid 62.8 ± 10.9 63.2 ± 11.4 0.063
Left parotid 63.2 ± 7.3 63.6 ± 7.4 0.156
Spinal cord 31.0 ± 8.0 30.3 ± 7.9 <0.001
Esophagus 62.9 ± 5.5 62.8 ± 5.5 0.500
Heart 57.9 ± 5.9 57.9 ± 6.0 0.527
Liver 49.2 ± 6.1 49.2 ± 6.1 0.094
Right kidney 36.3 ± 15.9 36.3 ± 16.0 0.406
Left kidney 37.2 ± 9.3 37.0 ± 9.1 0.406
Intestine 50.6 ± 3.7 50.7 ± 3.9 0.313
Bladder 56.1 ± 9.0 56.2 ± 8.9 0.156
Femoral head 39.7 ± 5.2 39.8 ± 5.3 0.156
Rectum 60.6 ± 8.9 60.2 ± 9.4 0.156
Table 6 Comparison of OARs Dmeanbetween the two
techniques (X  s)
OARs Dmean(Gy) SJT JTT p
Right lens 4.9 ± 2.0 3.38 ± 1.44 0.031
Left lens 5.0 ± 1.4 3.59 ± 1.07 0.031
Right eye 7.1 ± 3.8 5.56 ± 3.55 0.031
Left Eye 7.7 ± 2.6 5.99 ± 2.83 0.031
Right optic nerve 25.5 ± 12.4 23.87 ± 13.33 0.031
Left optic nerve 26.0 ± 11.1 24.37 ± 12.26 0.031
Brain stem 23.7 ± 13. 5 22.03 ± 14.08 0.016
Right parotid 29.3 ± 4.9 27.41 ± 4.02 0.031
Left parotid 28.7 ± 4.1 27.23 ± 3.46 0.031
Spinal cord 19.0 ± 8.0 18.1 ± 7.6 <0.001
Esophagus 29.4 ± 8.4 28.9 ± 8.1 0.016
Heart 17.9 ± 11.9 17.5 ± 11.8 0.004
Liver 12.2 ± 9.9 11.9 ± 9.8 0.031
Right kidney 8.5 ± 4.1 8.2 ± 4.0 0.031
Left kidney 6.6 ± 4.8 6.3 ± 4.5 0.031
Intestine 27.4 ± 3.4 27.1 ± 3.4 0.016
Bladder 33.5 ± 8.7 33.1 ± 8.5 0.004
Femoral head 14.1 ± 1.6 13.7 ± 1.5 0.004
Rectum 35.8 ± 4.5 35.2 ± 4.7 0.031
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between the two techniques. The JTT d-IMRT plans dis-
played significantly lower percentages of V5, V10, V20,
V30, V40 and significantly lower mean doses of the whole
body (p < 0.001). There was no significant difference of
maximum doses delivered to the whole body (p = 0.071).
Table 4 lists the statistical data of the lungs for all
thoracic cases. The V5, V10, V20, Dmean of lungs in JTT
d-IMRT plans are significantly lower than the corre-
sponding values of the SJT d-IMRT plans (p < 0.001),
the mean reduction was 2.6%, 1.3%, 0.6% and 0.4%, re-
spectively. There was no significant difference of maxi-
mum doses delivered to the lungs (p = 0.155).
This study demonstrates that the mean values of the
maximum doses to the lens, eyes, brainstem, spinal cord,
and right optic nerve are significantly reduced in the
JTT plans (all p values <0.05), as shown in Table 5. The
doses reduction for these OARs ranged from 2.2% to
28.6%, and the maximum dose to lens is reduced most
obviously.
Table 6 lists the mean doses to various OARs for all
patients. The JTT d-IMRT plans give significantly lower
mean doses to the studied OARs (all p values <0.05).
The mean doses reduction for these OARs ranged from
1.1% to 31.0%, and the reduction values are depend on
the volume and the location of the OARs.
Treatment plan verification of the two techniques is
generally performed with the γ evaluation method. The
γ was compared locally, and the γ pass rate for SJT and
JTT is 93.9 ± 1.98 and 94.1 ± 1.95, respectively. The com-
parison of γ between the two techniques showed no statis-
tical difference (p = 0.132). Dose calculation and delivery
are both accurate for SJT and JTT plans at criteria of
3%/3 mm using γ analysis.
Discussion
Jaw tracking methods have also been used in other treat-
ment modalities aiming to achieve better target coverage
and critical structure sparing. Joy et al. [4] evaluated the
dosimetric effects of jaw tracking in step-and-shoot IMRT,
showing an overall reduction of normal tissue doses. Most
patients had reductions of V5, V10, and V20 by less than
2% in the normal tissues. Schmidhalter et al. [5] evaluated
the leaf transmission reduction using moving jaws in dy-
namic MLC IMRT, and demonstrated that the undesired
doses to the body volume minus the planning target vol-
ume decreased by up to 1.8% and 1.5% for prostate and
H&N patients. Simultaneously, the MU increased by up to
3.1% and 2.8%, respectively. Kim et al. [6] assessed the po-
tential advantages of jaw tracking technique by using con-
trol point sequences of VMAT planning, showing that, for
H&N cases, the mean dose reductions for all the OARs
ranged from 4.3% to 11.9%, and for prostate patients, the
organs distant from the target were spared better in jaw-
Figure 1 DVH comparison between SJT and JTT plans for different body sites: (a) H&N, (b) Thoracic, (c) Abdominal, (d) Pelvic case.
CTV: Clinical target volume; PTV: Planning target volume; GTV: Gross tumor volume; PGTV: Planning gross tumor volume.
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more significant in the dose regions of D80, D90 and D95
for all the patients in JTSA plans.
However, previous studies [4-6] included no abdominal
cases or other pelvic lesion except prostate: the number of
OARs was less than that of this study. Moreover, they
didn’t indicate which cases and which organs would bene-
fit most from JTT.
This study selected cases of various body sites. For
large and complex targets, such as NPC, the large target
volumes are surrounded by many critical neural tissues
and sensitive structures such as lens, optic nerves, brain
stem, parotid glands and spinal cord. This study demon-
strates that the mean values of the maximum doses to
the lens, eyes, brainstem, spinal cord, and right optic
nerve are significantly reduced in the JTT plans (allp values <0.05) as shown in Table 5. Perhaps because
these OARs do not overlap with the target in the se-
lected cases, yet the left optic nerve and other OARs are
partially or wholly covered by PTVs. The reduction of
the maximum dose to OARs may reduce the risk of ra-
diation injury [7,8], such as radiation induced myelitis
and cataract. It is also more meaningful for the radio-
therapy patients with local recurrent or second primary
malignant lesion within or adjacent to a previously irra-
diated area.
The JTT technique also significantly reduces the low
dose regions. In the thoracic cases, the JTT technique
significantly reduces the V5, V10, V20 to the lungs, as
shown in Table 4, compared to the SJT plan (p < 0.001).
The results may mostly benefit Hodgkin’s lymphoma
patients whose lungs are largely within the treatment
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duce the risk of pulmonary toxicity since radiation
pneumonitis rate is correlated with low dose volumes
[9-12]. The risk of radiation induced secondary malig-
nancies is another concern, which is strongly associ-
ated with low dose exposure of normal tissues during
IMRT [13].
In addition, this study suggests that the JTT plans give
significantly lower mean doses to various OARs (all p
values <0.05, refer to Table 6 for details). The JTT asso-
ciated OAR dose reductions are more obvious for the
mean doses to the structures of small volume (such as
lens) or structures far from the targets (such as left optic
nerve, esophagus, and kidneys in this study). The mean
doses of OARs have been widely used to predict the
probability of radiation toxicity [9-12], such as pul-
monary toxicity. Therefore, JTT plans may decrease the
probability of developing late side effects or secondary
neoplasm.
Some problems exist in the current jaw tracking tech-
nique though. Firstly, jaw tracking is not considered in
the optimization of JTT d-IMRT or in the step-and-
shoot jaw tracking IMRT plans [4], as limited by the
optimization algorithm of TPS. However, the Eclipse
TPS (version 11.0) provides jaw tracking option in the
VAMT plan optimization, which is applicable on Varian
Truebeam accelerators. Secondly, the output factor of
the accelerator varies dramatically in jaw tracking tech-
nique. Usually, the output factors are measured on the
central axis of the beam. However, there are many off-
axis fields in jaw tracking plans, which would affect the
output factor and should be considered in treatment
planning. Joy et al. [4] calculated the off-axis output fac-
tors and demonstrated decreases of 1% to 3% when
shifting away from central axis. Although all the SJT and
JTT plans in this study can pass the dosimetric verifica-
tion, this issue was not solved so far and further re-
search is needed. Thirdly, the performance of flattening
filter-free (FFF) module combined with the jaw tracking
technique of TrueBeam accelerator is still uncertain.
There were several reports [14-19] about the clinical
usage of FFF beams, indicating more potential of redu-
cing the doses to OARs with comparable target dose
coverage. The potential benefit of applying jaw tracking
technique in FFF beams will be further studied in the
future work.
Conclusions
This study demonstrates that all the SJT and JTT plans
could meet the clinical objectives and are clinically ap-
plicable. The dose measurements agreed well with TPS
calculated doses. JTT displays superior OARs sparing
than SJT plans. These results are of clinical importance,
especially for the patients with large and complex targetsbut close to some highly radio-sensitive organs to spare
(such as lens or gonad), and for patients with local re-
current or secondary primary malignant lesion within a
previously irradiated area. More studies on off-axis output
factors and combined application of FFF module should
be conducted in the future.
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